Recent News & Events
 

Nuvelo and ARCA biopharma Announce Merger Agreement Creating Late-Stage Cardiovascular Biotechnology Company

Bucindolol Significantly Reduces Hospitalization and Death in Heart Failure Patients with Very Favorable Genotypes

ARCA biopharma's Chief Science and Medical Officer Receives Lifetime Achievement Award at Annual Heart Failure Meeting

FDA Accepts New Drug Application for Bucindolol, A Genetically-Targeted Treatment for Heart Failure from ARCA biopharma
About

ARCA biopharma, Inc. is a biopharmaceutical company developing genetically-targeted therapies for heart failure and other cardiovascular diseases. ARCA began operations in 2005 and is headquartered in Broomfield, Colorado.
 
Science

ARCA is currently developing bucindolol for the treatment of heart failure. ARCA anticipates submitting an application with the FDA for approval of bucindolol in 2008. Bucindolol will have market exclusivity through 2024.
 
           
ARCA ©2008 ARCA biopharma | Home | Site Map